Evidence map›Paper›PMID 30897785›Full record

ArticleMolecules (Basel, Switzerland)2019

Autofluorescence Imaging Reflects the Nuclear Enlargement of Tumor Cells as well as the Cell Proliferation Ability and Aberrant Status of the

Kentaro Moriichi, Mikihiro Fujiya, Yu Kobayashi, Yuki Murakami, Takuya Iwama, Takehito Kunogi, Takahiro Sasaki, Masami Ijiri, Keitaro Takahashi, Kazuyuki Tanaka and 10 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

Kentaro MoriichiDivision of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan. morimori@asahikawa-med.ac.jp.
Mikihiro FujiyaDivision of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan. fjym@asahikawa-med.ac.jp.
Yu KobayashiDivision of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan. kobayu@asahikawa-med.ac.jp.
Yuki MurakamiDivision of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan. yuuki1228@asahikawa-med.ac.jp.
Takuya IwamaDivision of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan. ganmatakuya@asahikawa-med.ac.jp.
Takehito KunogiDivision of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan. kunogi@asahikawa-med.ac.jp.
Takahiro SasakiDivision of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan. taka-sas@asahikawa-med.ac.jp.
Masami IjiriDivision of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan. m-ijiri@asahikawa-med.ac.jp.
Keitaro TakahashiDivision of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan. ktakaha@asahikawa-med.ac.jp.
Kazuyuki TanakaDivision of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan. kazuyuki@asahikawa-med.ac.jp.
Aki SakataniDivision of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan. sakatani@asahikawa-med.ac.jp.
Katsuyoshi AndoDivision of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan. k-ando@asahikawa-med.ac.jp.
Yoshiki NomuraDivision of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan. nomuzo@asahikawa-med.ac.jp.
Nobuhiro UenoDivision of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan. u-eno@asahikawa-med.ac.jp.
Shin KashimaDivision of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan. shin1014@asahikawa-med.ac.jp.
Katsuya IkutaDivision of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan. ikuta@asahikawa-med.ac.jp.
Hiroki TanabeDivision of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan. tant@asahikawa-med.ac.jp.ORCID 0000-0001-9029-5081
Yusuke MizukamiDivision of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan. mizu@asahikawa-med.ac.jp.ORCID 0000-0002-1068-7024
Yusuke SaitohDigestive Disease Center, Asahikawa City Hospital, Asahikawa 070-8610, Japan. y_saito@city.asahikawa.hokkaido.jp.
Toshikatsu OkumuraDivision of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan. okumurat@asahikawa-med.ac.jp.
Asahikawa Medical University · JPAsahikawa City Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAutofluorescence imaging (AFI) is useful for diagnosing colon neoplasms, but what affects the AFI intensity remains unclear. This study investigated the association between AFI and the histological characteristics, aberrant methylation status, and aberrant expression in colon neoplasms.

methodsFifty-three patients with colorectal neoplasms who underwent AFI were enrolled. The AFI intensity (F index) was compared with the pathological findings and gene alterations. The F index was calculated using an image analysis software program. The pathological findings were assessed by the tumor crypt density, cell densities, and N/C ratio. The aberrant methylation of

resultsAn increased N/C ratio, the aberrant expression of

conclusionsAFI reflects the nuclear enlargement of tumor cells, the cell proliferation ability, and the altered status of cell proliferation-related genes, indicating that AFI is a useful and practical method for predicting the dysplastic grade of tumor cells and cell proliferation.

Indexed as

CadherinsColonic NeoplasmsColonoscopesCore Binding Factor Alpha 3 SubunitCyclin-Dependent Kinase Inhibitor p16HumansImmunohistochemistryKi-67 AntigenMutL Protein Homolog 1Optical ImagingSoftwareTumor Suppressor Protein p53CadherinsCore Binding Factor Alpha 3 SubunitCyclin-Dependent Kinase Inhibitor p16Ki-67 AntigenMLH1 protein, humanMutL Protein Homolog 1Tumor Suppressor Protein p53autofluorescence imagingcolon neoplasmmethylationN/C ratiotumor cell proliferation

Identifiers

PMID30897785
PMCPMC6471796
OpenAlexW2923838784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.